$1.11
0.00 (-0.43%)
Open$1.13
Previous Close$1.11
Day High$1.13
Day Low$1.11
52W High$6.75
52W Low$1.10
Volume—
Avg Volume10.5K
Market Cap2.00M
P/E Ratio—
EPS$-4.00
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,809.0% upside
Current
$1.11
$1.11
Target
$21.19
$21.19
$14.35
$21.19 avg
$22.63
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 842.6K | 775.9K | 707.6K |
| Net Income | 53.5K | 41.0K | 38.8K |
| Profit Margin | 6.3% | 5.3% | 5.5% |
| EBITDA | 84.6K | 70.9K | 63.0K |
| Free Cash Flow | 39.3K | 30.9K | 34.5K |
| Rev Growth | +2.0% | +16.5% | +21.7% |
| Debt/Equity | 0.16 | 0.21 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |